Approaches for skeletal gene therapy

Critical Reviews in Eukaryotic Gene Expression

Volumn 12, Issue 3, 2002, Pages 163-173

  Niyibizi, Christopher ^a   Wallach, Corey J ^a   Mi, Zhibao ^a   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense gene therapy; Cellular transplantation; Gene therapy; Musculoskeletal diseases; Osteogenesis imperfecta

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLLAGEN TYPE 1; FLUORIDE; MAGNESIUM; PAMIDRONIC ACID; PROCOLLAGEN; PROCOLLAGEN IALPHA 1; PROCOLLAGEN IALPHA 2; UNCLASSIFIED DRUG;

ALLELE; ANTISENSE THERAPY; BONE CELL; CELL TRANSPLANTATION; GENE ISOLATION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC CODE; HUMAN; MEDICAL RESEARCH; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; COLLAGEN; DNA, ANTISENSE; GENE THERAPY; HUMANS; MICE; MUTATION; OSTEOGENESIS IMPERFECTA; RNA;

EID: 0041382372     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v12.i3.10     Document Type: Review

References (42)

1. Barsh GS, David KE, Byers PH (1982): Type I osteogenesis imperfecta: a nonfunctional allele for pro alpha 1 (I) chains of type I procollagen. Proc Natl Acad Sci U S A 79:3838-3842.
2. Bischoff H, Freitag P, Jundt G, Steinmann B, Tyndall A, Theiler R (1999): Type I osteogenesis imperfecta: diagnostic difficulties. Clin Rheumatol 18:48-51.
3. Byers PH, Starman BJ, Cohn DH, Horwitz AL (1988): A novel mutation causes a perinatal lethal form of osteogenesis imperfecta. An insertion in one alpha 1(I) collagen allele (COL1A1). J Biol Chem 263:7855-761.
4. Byers PH, Steiner RD (1992): Osteogenesis imperfecta. Annu Rev Med 43:269-282.
5. Caplan AI (1991): Mesenchymal stem cells. J Orthop Res 9:641-650.
6. Castells S (1973): New approaches to treatment of osteogenesis imperfecta. Clin Orthop 93:239-49.
7. Castells S, Colbert C, Chakrabarti C, Bachtell RS, Kassner EG, Yasumura S (1979): Therapy of osteogenesis imperfecta with synthetic salmon calcitonin. J Pediatr 95:807-811.
8. Castells S, Inamdar S, Baker RK, Wallach S (1972): Effects of porcine calcitonin in osteogenesis imperfecta tarda. J Pediatr 80:757-762.
9. Charnas LR, Marini JC (1993): Communicating hydrocephalus, basilar invagination, and other neurologic features in osteogenesis imperfecta. Neurology 43:2603-2608.
10. Chen Y (2001): Orthopedic applications of gene therapy. J Orthop Sci 6:199-207.
11. Chipman SD, Sweet HO, McBride DJ Jr, Davisson MT, Marks SC Jr, Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR (1993): Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A 90:1701-1705.
12. Dawson PA, Marini JC (2000): Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res 28:4013-4020.
13. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R (2001): Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 29:244-255.
14. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997): Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747-754.
15. Duzgunes N, Simoes S, Konopka K, Rossi JJ, Pedroso De Lima MC (2001): Delivery of novel macromolecular drugs against HIV-1. Expert Opin Biol Ther 1:949-970.
16. Evans CH, Robbins PD (1995): Possible orthopaedic applications of gene therapy. J Bone Joint Surg Am 77:1103-1114.
17. Flake AW, Roncarolo MG, Puck JM, Almeida-Porada G, Evans MI, Johnson MP, Abella EM, Harrison DD, Zanjani ED (1996): Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 335:1806-1810.
18. Forlino A, Marini JC (2000): Osteogenesis imperfecta: prospects for molecular therapeutics. Mol Genet Metab 71:225-232.
19. Garretsen AJ, Cremers CW, Huygen PL (1997): Hearing loss (in nonoperated ears) in relation to age in osteogenesis imperfecta type I. Ann Otol Rhinol Laryngol 106:575-582.
20. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998): Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
21. Grassi G, Forlino A, Marini JC (1997): Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res 25:3451-3458.
22. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK (1999): Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309-313.
23. Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK (2001): Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97:1227-1231.
24. Hou Z, Nguyen Q, Frenkel B, Nilsson SK, Milne M, van Wijnen AJ, Stein JL, Quesenberry P, Lian JB, Stein GS (1999): Osteoblast-specific gene expression after transplantation of marrow cells: implications for skeletal gene therapy. Proc Natl Acad Sci U S A 96:7294-7299.
25. Laptev AV, Lu Z, Colige A, Prockop DJ (1994): Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA. Biochemistry 33:11033-11039.
26. Lund AM, Nicholls AC, Schwartz M, Skovby F (1997): Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/IV. Acta Paediatr 86:711-718.
27. Mackenzie TC, Flake AW (2001): Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. Blood Cells Mol Dis 27:601-604.
28. Niyibizi C, Smith P, Mi Z, Phillips CL, Robbins P (2001): Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo. J Cell Biochem 83:84-91.
29. Oyama M, Tatlock A, Fukuta S, Kavalkovich K, Nishimura K, Johnstone B, Robbins PD, Evans CH, Niyibizi C (1999): Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging. Gene Ther 6:321-329.
30. Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD, Bagasra O, Prockop DJ (1995): Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 92:4857-4861.
31. Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, Simon D, Livezey K, Prockop DJ (1998): Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A 95:1142-1147.
32. Pittenger MF, Mackay AM, Beck SC, et al (1999): Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
33. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000): Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
34. Primorac D, Rowe DW, Mottes M, Barisic I, Anticevic D, Mirandola S, Gomez Lira M, Kalajzic I, Kusec V, Glorieux FH (2001): Osteogenesis imperfecta at the beginning of bone and joint decade. Croat Med J 42:393-415.
35. Prockop DJ (1997): Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74.
36. Prockop DJ, Baldwin CT, Constantinou CD (1990): Mutations in type I procollagen genes that cause osteogenesis imperfecta. Adv Hum Genet 19:105-132.
37. Rodan GA, Martin TJ (2000): Therapeutic approaches to bone diseases. Science 289:1508-1514.
38. Rowe DW, Shapiro JR, Poirer M, Schlesinger S (1985): Diminished type I collagen synthesis and reduced alpha 1(I) collagen messenger RNA in cultured fibroblasts from patients with dominantly inherited (type I) osteogenesis imperfecta. J Clin Invest 76:604-611.
39. Shapiro JR, Chipman SD (1992): Osteogenesis Imperfecta. In Kang AH, Nimni ME (eds), Collagen, Volume V, Pathobiochemistry, 1st ed., vol. V. Boca Raton, FL: CRC Press, pp. 49-86.
40. Sillence DO, Rimoin DL (1978): Classification of osteogenesis imperfect. Lancet 1:1041-1042.
41. Suzuki K, Oyama M, Faulcon L, Robbins PD, Niyibizi C (2000): In vivo expression of human growth hormone by genetically modified murine bone marrow stromal cells and its effect on the cells in vitro. Cell Transplant 9:319-327.
42. Wang Q, Marini JC (1996): Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 97:448-454.